08:31 AM EDT, 06/27/2024 (MT Newswires) -- Purple Biotech ( PPBT ) said Thursday that additional interim data from a mid-stage study of its experimental drug CM24, combined with Bristol Myers Squibb's ( BMY ) nivolumab and chemotherapy for pancreatic cancer patients, could improve overall survival.

Purple Biotech ( PPBT ) said the interim biomarker analysis showed that baseline serum myeloperoxidase levels below the threshold may predict overall survival improvement in patients treated with combination therapy compared to standard of care.

The company said the data also showed a reduced risk of death and cancer progression, prolongation of overall survival and progression-free survival, higher objective response rate and disease control rate, and decreasing CA19-9 levels in patients treated with the combination treatment.

Further data and results from the study are expected in H2.

Shares of Purple Biotech ( PPBT ) were up 21% in recent Thursday premarket activity.

Price: 0.5701, Change: +0.10, Percent Change: +21.30